1. Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles.
- Author
-
Swart, Laura E., Fens, Marcel H. A. M., van Oort, Anita, Waranecki, Piotr, Mata Casimiro, L. Daniel, Tuk, David, Hendriksen, Martijn, van den Brink, Luca, Schweighart, Elizabeth, Seinen, Cor, Nelson, Ryan, Krippner-Heidenreich, Anja, O'Toole, Tom, Schiffelers, Raymond M., Kooijmans, Sander, and Heidenreich, Olaf
- Subjects
- *
BONE marrow cells , *BLOOD diseases , *PROGENITOR cells , *LIPIDS , *STEM cells - Abstract
Lipid nanoparticles (LNPs) have evolved rapidly as promising delivery systems for oligonucleotides, including siRNAs. However, current clinical LNP formulations show high liver accumulation after systemic administration, which is unfavorable for the treatment of extrahepatic diseases, such as hematological disorders. Here we describe the specific targeting of LNPs to hematopoietic progenitor cells in the bone marrow. Functionalization of the LNPs with a modified Leu-Asp-Val tripeptide, a specific ligand for the very-late antigen 4 resulted in an improved uptake and functional siRNA delivery in patient-derived leukemia cells when compared to their non-targeted counterparts. Moreover, surface-modified LNPs displayed significantly improved bone-marrow accumulation and retention. These were associated with increased LNP uptake by immature hematopoietic progenitor cells, also suggesting similarly improved uptake by leukemic stem cells. In summary, we describe an LNP formulation that successfully targets the bone marrow including leukemic stem cells. Our results thereby support the further development of LNPs for targeted therapeutic interventions for leukemia and other hematological disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF